Figure 2
GPG-NH 2 and its metabolites G-NH 2 and αHGA decrease gp160 mobility and steady-state levels. (A) Scheme of GPG-NH2 being metabolized in cell culture medium supplemented with 10% FBS. GPG-NH2 is processed by CD26 (peptidyl peptidase V) to G-NH2 and subsequently modified into αHGA by an unidentified enzyme. (B) HeLa-tat III cells were transfected to express gp160. Two hours post transfection the cells were treated with the indicated concentrations of GPG-NH2, G-NH2 or αHGA and harvested 20 h post transfection. The cell lysates were separated by SDS-PAGE and immunoblotted with mAb towards gp41. (C) Densitometric measurement of gp160 and degradation products (left panel) and gp41 (right panel) given as percentage of total gp160 or gp41 respectively in untreated cells in (B), lane 1. The results represent the average of two experiments.